Non-Hodgkin Lymphoma in Jamaica and its Relation to Adult T-Cell Leukemia-Lymphoma

  1. WILLIAM N. GIBBS, M.D.;
  2. WYCLIFFE S. LOFTERS, M.B.;
  3. MARIE CAMPBELL, M.D.;
  4. BARRIE HANCHARD, M.B.;
  5. LOIS LaGRENADE, M.B.;
  6. BEVERLEY CRANSTON, B.Sc;
  7. JAN HENDRIKS, M.Sc;
  8. ELAINE S. JAFFE, M.D.;
  9. CARL SAXINGER, Ph.D.;
  10. MARJORIE ROBERT-GUROFF, Ph.D.;
  11. ROBERT C. GALLO, M.D.;
  12. JEFFREY CLARK, M.D.; and
  13. WILLIAM A. BLATTNER, M.D.
  1. Kingston, Jamaica; and Bethesda, Maryland

    Abstract

    Of 95 patients consecutively diagnosed with non-Hodgkin lymphoma, 52 (55%) had antibodies to human T-cell leukemia-lymphoma virus, type I. Antibody positivity was strongly associated with skin involvement, leukemia, and hypercalcemia (p < 0.02). Two patients had systemic opportunistic infections. Neither meningeal nor lung infiltration was detected, and lymph node infiltration was diffuse in all patients. Of 36 patients who received immunophenotypic classifications, 30 had diseases that affected the T-cell system, and the cells of all tested patients with these diseases showed the helper/inducer (T4) phenotype. Twenty-seven of these thirty-six patients were found to have adult T-cell leukemia-lymphoma, and of the 27, 24 had antibodies to HTLV-I. The median duration of survival in patients with adult T-cell leukemia-lymphoma was 17 weeks, but a subgroup of 9 patients had indolent courses and a median survival of 81 weeks, which suggests that the disease has differing expression with courses that range from smoldering and indolent to acute and rapidly fatal. Hypercalcemia was the most important prognostic determinant of adult T-cell leukemia-lymphoma.

    Article and Author Information

    • ▸From the Departments of Pathology and Medicine, University of the West Indies, and Immunology Unit of Jamaica; Kingston, Jamaica; and Environmental Epidemiology Branch and Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health; Bethesda, Maryland.

    • Grant support: in part by grant N01-CP-31006 from the National Cancer Institute of the National Institutes of Health, Bethesda, Maryland.

    • ▸ Requests for reprints should be addressed to: William N. Gibbs, M.D.; World Health Organization, Room L423; 1211 Geneva 27 Switzerland.

    « Previous | Next Article »Table of Contents